Clinical trials: Phase 1b, open to volunteers
Phase 1b, HC-7366
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
To find out if the combination of HC-7366 and nivolumab (with or without ipilimumab) can help to control ccRCC. The
- Conditions
- Phase 1b, HC-7366, SHARK, Kidney Cancer
- Trial name
- NCT07401875
- Testing
- Nivolumab, HC-7366, ipilimumab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Phase 1b, Open Label
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
- Conditions
- Phase 1b, Open Label, REC-617, RB1-Negative
- Trial name
- NCT07633756
- Testing
- REC617
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center